Healio (3/5, Gramigna) reports, “The current body of research regarding psychedelics has produced insufficient evidence to recommend FDA approval of any psychedelic compound for routine clinical use in psychiatric disorders,” research indicated, but investigators “noted the need to further study the efficacy of psychedelics for treating psychiatric disorders.” Included in the medical literature review study were “14 articles that reported on well-designed clinical trials investigating the efficacy of LSD, MDMA, psilocybin and ayahuasca for the treatment of anxiety and mood disorders, substance-related and addictive disorders, and trauma and stress-related disorders, as well as in end-of-life care.” The findings were published online Feb. 26 in the American Journal of Psychiatry, a publication of the American Psychiatric Association.
Related Links:
— “Psychedelics appear promising for treating psychiatric disorders, but more research needed, “Joe Gramigna, Healio, March 5, 2020